1 / 52

Carbohydrates

Carbohydrates. Monosaccharides. D-glucose. D-galactose. Reducing substance : hydroxyl group near an aldehyde or ketone group can react with Cu 2+ , converting it to Cu +. D-glucose. D-fructose. Disaccharides. reducing end. Lactose. reducing end. Maltose. Sucrose. not a reducing

early
Download Presentation

Carbohydrates

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Carbohydrates • Monosaccharides D-glucose D-galactose

  2. Reducing substance: hydroxyl group near an aldehyde or ketone group can react with Cu2+, converting it to Cu+ D-glucose D-fructose

  3. Disaccharides reducing end Lactose

  4. reducing end Maltose

  5. Sucrose not a reducing substance

  6. Polysaccharides reducing end Cellulose

  7. Amylopectin Glycogen branches about every 24-30 linear linkages branches every 8-12 glucose units

  8. Intestinal absorption of carbohydrates microvilli Jejunum villi

  9. Intestinal absorption of carbohydrates MICROVILLI BRUSH BORDER GUT BLOOD 1 maltose a -amylase Starch saliva and pancreatic juice glucose Glycogen sucrose 2 fructose 3 lactose galactose galactose Monosaccharides glucose fructose

  10. Glucose Production Glucose Consumption 125g Blood glucose brain Glucose 50g Glycogen (75%) 50g rbc wbc muscle fat cell

  11. Glucose transporters *insulin low…GLUT4 in intracellular compartments; insulin high…GLUT4 translocates to membrane

  12. Glucose Production Glucose Consumption CO2 125g Blood glucose brain Glucose 50g Glycogen (75%) 50g rbc wbc pyruvate lactate (10-15%) certain amino acids (10-15%) CO2 glycerol (2%) muscle fat cell

  13. Regulation of blood glucose • Glycogenesis: glucose glycogen (liver, muscle) • Glycogenolysis: glycogen glucose • Gluconeogenosis: non-CHO sources glucose • Glycolysis: glucose CO2 + H2O + ATP • Renal threshold: proximal convoluted tubule

  14. Regulation of blood glucose stimulates Somatostatin inhibits d Pancreatic Islet a b Cortisol Growth hormone glucose glucagon Insulin epinephrine Glycogenolysis Gluconeogenesis Glucose uptake Glycolysis Glucose uptake Lipogenesis Muscle Liver Adipose tissue

  15. Determination of glucose • Specimens used • whole blood • used with home glucose monitoring units • cellular use of glucose gives 7% decrease/hour • NaF preserves glucose 24hr, RT • cannot use such a specimen for enzyme assays, especially urease • lithium iodoacetate preserves glucose; does not interfere with urease • capillary blood = fasting venous level + 5 mg/dL • plasma, serum • 10-15% higher level than whole blood glucose • RI: 70-105 mg/dL • CSF • RI: 60-70% plasma glucose = 40-70 mg/dL • urine • RI: <30 mg/dL random; <500 mg/24 hr

  16. Glucose Methods HK • hexokinase glucose + ATP gluc-6-PO4 + ADP gluc-6-PO4 + NAD+ 6-phosphogluconate + NADH + H+ INT + NADH + H+formazan + NAD+ • most widely used • reference method against which others are compared • serum, plasma and urine • avoid hemolysis G6PD PMS

  17. Glucose Methods • glucose oxidase • glucose + O2 gluconic acid + H2O2 • H2O2 + reduced dye oxidized dye+ H2O • peroxidase reaction interference by uric acid, vitamin C, bilirubin • suitable for spinal fluid • measure O2 consumption via pO2 electrode • suitable for all body fluids • measure H2O2 production via H2O2 electrode • suitable for plasma, serum, whole blood GO POD

  18. Glucose Methods GDH • glucose dehydrogenase glucose + NAD+ D-gluconolactone + NADH + H+ • highly specific as “GDH-NAD”, with little interference, EXCEPT… • Pyrroloquinolinequinone (“GDH-PQQ”) • 2005 FDA warning • giving false increased glucose readings when patient is receiving maltose, icodextrin (dialysis), galactose, d-xylose

  19. Glucose Methods GDH • glucose dehydrogenase glucose + NAD+ D-gluconolactone + NADH + H+ • highly specific as “GDH-NAD”, with little interference, EXCEPT… • Pyrroloquinolinequinone (“GDH-PQQ”) • 2005 FDA warning • giving false increased glucose readings when patient is receiving maltose, icodextrin (dialysis), galactose, d-xylose • Coulometry • http://www.medisense.com/au • FreeStyle glucometer, Abbott Laboratories • Electrons released in the reaction are measured as a current • Allows very small volume (0.3 uL) to be used, with results in 15 seconds

  20. Glucose Methods • oxidation-reduction reactions Fe3+Fe2+ or Cu2+Cu1+ • least specific for glucose

  21. Clinical Significance • Hyperglycemia • diabetes mellitus • endocrine disorders • acromegaly: incr. growth hormone • Cushing’s syndrome: incr. cortisol • thyrotoxicosis: incr. T4 • pheochromocytoma: incr. epinephrine • drugs • certain anesthetics • steroids

  22. Clinical Significance • Hypoglycemia • insulin overdose • drugs • sulfonylureas • antihistamines • alcoholism (long term) • insulinoma • galactosemia • glycogen storage diseases

  23. Expert Committee on the Diagnosis and Classification of DM - 2005 • Diagnosis of Diabetes Mellitus • Symptoms of diabetes mellitus • Polyuria • Polydipsia • Unexplained weight loss • Any TWO of the following tests, on different days • Casual plasma glucose > 200 mg/dL • Fasting plasma glucose (FPG) > 126 mg/dL • 2hr Post prandial glucose (PPG) > 200 mg/dL after a meal with 75g glucose load

  24. Expert Committee on the Diagnosis and Classification of DM - 2005 • Type 1 • Type 1a • characterized by beta cell destruction caused by an autoimmune process, usually leading to absolute insulin deficiency • patients must take insulin to survive • usually young, with acute onset (days to weeks) • islet-cell antibodies usually present • Type 1b • idiopathic

  25. Expert Committee on the Diagnosis and Classification of DM - 2005 • Type 2 • insulin resistance in peripheral tissue and an insulin secretory defect of the beta cell • variable [insulin] • highly associated with a family history of diabetes, older age (>40), obesity and lack of exercise • more common in • Women • African American • Hispanics • Native Americans

  26. Expert Committee on the Diagnosis and Classification of DM - 2005 • “Other specific types” • pancreatic, hormonal disease • Pancreatitis, cystic fibrosis • Acromegaly (GH), Cushing’s syndrome (cortisol) • drug/chemical toxicity • insulin receptor abnormalities • no renal or retinal complications

  27. Expert Committee on the Diagnosis and Classification of DM - 2005 • Gestational diabetes mellitus • pregnancy • frequent but transitory glucose intolerance • greater risk of perinatal complications • placental lactogen? • > 140 mg/dL one hour after 50-g glucose load screening • TWO of four results abnormal in 100 g glucose load test: • fasting plasma glucose > 105 mg/dL • > 195 mg/dL at 1 hr • > 165 mg/dL at 2 hrs • > 145 mg/dL at 3 hrs

  28. National Diabetes Association 2003 • Pre-diabetes • http://diabetes.niddk.nih.gov/dm/pubs/diagnosis/index.htm • http://www.diabetes.org/pre-diabetes.jsp • Fasting Plasma Glucose Diagnosis Result (mg/dL) • 70 – 99 Normal • 100 to 125 Pre-diabetes (impaired fasting glucose) • 126 and above Diabetes mellitus* • *Confirmed by repeating the test on a different day.

  29. Clinical Significance • Glucose tolerance test (still used for gestational diabetes diagnosis) • patient preparation • normal diet three days prior to test • no food after regular evening meal on day before test • take fasting blood, urine specimen • drink 100 g glucose load within 5 minutes • allow water, but no food, chewing gum, smoking, exercise during test • specimens taken 1, 2, 3 hours after ingestion 200 Plasma glucose (mg/dL) Diabetic Normal 100 60 120 180 Minutes after glucose ingestion

  30. Clinical Significance • Other conditions, tests associated with diabetes mellitus • white cell antigens • HLA types DR3, DR4, DQB1*0302 • Note that diabetes resistance genes = DR2, DQB1*0602 • lipid studies • hyperlipoproteinemia type IV • increased TG • microalbuminuria • microangiopathies • retinal, renal, neural

  31. Management of diabetes mellitus • Glycated hemoglobin (A1) COOH COOH COOH COOH H2N H2N H2N H2N COOH COOH H2N H2N N N glu glu non-enzymatic process conversion of HbA into HbA1 at N-terminal valine

  32. Management of diabetes mellitus • Glycated hemoglobin • irreversible reaction occurring throughout the 120-day life span of rbc • reflects timed average [glucose] over previous 4-8 weeks • HbA1c = 80% total glycohemoglobin • reference range: 3-6% total Hgb • uncontrolled diabetes mellitus: 12-20% total Hgb • controlled: 9-12% total Hgb • Considerations when measuring HbA1c • abnormal hemoglobins can also be glycated • variability in levels of “labile fraction” (intermediates)

  33. Management of diabetes mellitus For every 1% decrease in HbA1c, risk of microvascular complications is reduced by 35% Diabetes Care 2000, 23: S27-S31

  34. Management of diabetes mellitus • Manual Methods for HbA1c compared Ion-exchange chromatography Affinity Chromatography + HbA--Val--N | CH2 | C=O | HOCH | HCOH | HCOH | CH2OH Principle + + + + HbA HbA1c + + + + pba -- - - - - - - - - - - - - - - -- -- - - pba pba “Fast fraction” HbA1c elutes first HbA1c elutes last pba Phenylboronic acid

  35. Management of diabetes mellitus • Manual Methods for HbA1c compared • other non-glycated Hb measured • IEC: HbF and any others with charge like A1 • AC: none • time • IEC: 2-3 hrs • AC: 15 minutes • glycated hemoglobins measured • IEC: A1a, 1b, 1c only • AC: any glycated hemoglobin, including abnormals • temperature sensitive? • IEC: yes • AC: no

  36. Management of diabetes mellitus • Automated Method for HbA1c • High pressure liquid chromatography (HPLC) • Cation exchange method • the eluant must be __________________ • The first form of hemoglobin eluting from the column must be _________________________ • The last form of hemoglobin eluting from the column must be __________________________

  37. Management of diabetes mellitus • Attempts to convert HbA1c value to “mean blood glucose” value • Nathan et al, 1984 using linear regression on data from 21 patients • 33.3 (%HbA1c) – 86 • Examples: 6.0% = ~115 mg/dL 7.5% = ~165 mg/dL 9.0% = ~215 mg/dL

  38. Management of diabetes mellitus • Revised calculation, effective 3/21/05 • Rohlfing et al, 2002 using comparison data from 1500 patients • (35.6 x %HbA1c) – 77.3 • Examples: 6.0% = ~136 mg/dL 7.5% = ~190 mg/dL 12.0% = ~350 mg/dL • Only valid for A1c values between 6 and 12%

  39. Management of diabetes mellitus • Glycated serum proteins • albumin (“fructoseamine”) • turnover = 2-3 weeks • rapid method using tetrazolium dye reduction colored product

  40. Carbohydrate inborn errors of metabolism • Glycogen storage diseases • lack of enzymes of glycogen metabolism • incr. tissue glycogen • results in severely limited lifespan • von Gierke’s disease • liver cells lack glucose-6-phosphatase glucose-6-PO4 blood glucose triose phosphate pyruvate

  41. Carbohydrate inborn errors of metabolism • Lactose intolerance • deficiency in intestinal mucosal lactase • GTT done as baseline • 2nd day, give lactose instead of glucose • normal: normal GTT curve • abnormal: flat curve ( and much pain!)

  42. Carbohydrate inborn errors of metabolism • Galactosemia (1) galactose galactose-1-PO4 galactilol (2) galactose-1-PO4 UDP-galactose (3) UDP-galactose UDP-glucose cataracts (4) UDP-glucose glucose-1-PO4 • deficiency in uridyl transferase * • results in galactosuria, retardation, cataracts, no conjugation of bilirubin • urine tests * gal. oxidase galactose + O2 galactose dialdehyde + H2O2

  43. Ketones • Complication of uncontrolled diabetes mellitus • Acid-base imbalance • Can be life-threatening • Acetone, acetoacetate, b-hydroxybutyrate Blood ketones amino acids acetyl CoA fatty acids Ketones acetoacetate B-hydroxybutyrate acetate CO2 TCA cycle H2O ATP

  44. Ketones • Complication of uncontrolled diabetes mellitus • Sodium nitroprusside • B-hydroxybutyrate dehydrogenase Blood ketones amino acids acetyl CoA fatty acids Ketones acetoacetate B-hydroxybutyrate acetate CO2 TCA cycle H2O ATP

  45. Extra slides

  46. Glycogenesis, glycogenolysis • Hormones involved • fed: insulin from pancreatic beta cells (Islets of Langerhans) • preproinsulin proinsulin (A, B and C peptides) insulin + C-peptide • anabolic (synthesis) • promotes cellular uptake of glucose • increased: • lipogenesis • protein synthesis • glycogenesis • decreased: • lipolysis • ketone formation • gluconeogenesis • glycogenolysis

  47. Glycogenesis, glycogenolysis • Hormones involved • fasting: glucagon from pancreatic alpha cells • catabolic • liver: glycogen converted to glucose, released into blood • muscle: glycogen converted to glucose-6-PO4, remains in the muscle cell for its own energy needs • “fight or flight” : epinephrine from adrenal medulla • action similar to glucagon

  48. Glycogenesis, glycogenolysis • Stimulation of insulin release • glucose • leucine, arginine, histidine, phenylalanine • sulfonylureas (tolbutamides) • ACTH, GH • Inhibition of insulin release • thiazide diuretics • dilantin (antiseizure) • human placental lactogen (diabetes of pregnancy) • Decreased tissue response to insulin • glucocorticoids obesity • estrogens inactivity • progestins low CHO diet

More Related